Damora Therapeutics, Inc.
DMRA
$24.16
$1.074.63%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -878.77% | 25.17% | 34.74% | 40.01% | 44.10% |
| Total Depreciation and Amortization | -81.22% | -105.82% | -97.02% | -88.47% | -78.19% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3,383.87% | -32.63% | -27.93% | -17.35% | 6.51% |
| Change in Net Operating Assets | 788.56% | 110.27% | 99.54% | 89.87% | 38.97% |
| Cash from Operations | 63.88% | 51.40% | 55.74% | 55.13% | 49.55% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -100.00% | -100.00% | -77.38% | -47.63% |
| Cash from Investing | -249.13% | -100.00% | -100.00% | -77.45% | -47.83% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | 322.40% | -70.62% | 232.61% | -109.39% | -182.55% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3,439.49% | -255.06% | -13,358.51% | -130.12% | 35.61% |